Cargando…
Oh, how hard it is to open the gate for sepsis trials: lessons from SCARLET
Although SCARLET could not achieve its primary end‐point, the conditions of this trial were different from that of clinical practice in Japan. The effectiveness of the anticoagulant therapy for septic disseminated intravascular coagulation should be examined further in future studies.
Autores principales: | Iba, Toshiaki, Tanaka, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328919/ https://www.ncbi.nlm.nih.gov/pubmed/30651991 http://dx.doi.org/10.1002/ams2.372 |
Ejemplares similares
-
Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis
por: Yamakawa, Kazuma, et al.
Publicado: (2019) -
Oh, the Lessons We Have Learned!
por: Zimmerman, Karen G., et al.
Publicado: (2017) -
Scarlet Fever
Publicado: (1881) -
Scarlet Fever Scare
Publicado: (1893) -
Scarlet Fever in England
Publicado: (1864)